- Company name
- Constellation Software
- Sector
- Diversified software
- About
- Constellation Software buys small software companies. Each company makes software for one specific industry, such as public transit, libraries, or local government. Customers depend on this software to run daily operations, so they rarely switch to a new system. Constellation earns most of its money from maintenance fees and recurring subscriptions. It almost never sells a company after it buys it.
- Thesis
- Investors worry that cheap AI tools will let rivals copy Constellation's niche, industry-specific software. This fear grew when organic growth slowed to 3% in the second quarter of 2026, or 1% after currency effects. Organic growth of maintenance and recurring revenue fell to 2% after currency effects, its lowest rate in at least two years, and recovered only to 4% in Q3 2026, because Altera and the US healthcare businesses keep losing customers. Founder Mark Leonard also resigned as President for health reasons in 2025 and left the board in May 2026. Constellation's software runs core, regulated tasks such as utility billing or court case management. Customers rarely remove this kind of system, since a failure would disrupt daily operations. This makes a quick AI clone unlikely to displace it. But the new President, Mark Miller, has not yet run the company's acquisition process through a full economic cycle without Leonard. S&P raised its outlook on Constellation in August 2026 because leverage fell, so the balance sheet is not the market's main worry. The first test is whether organic growth of recurring revenue returns to about 5%, the rate Miller calls normal. Management said that $17 million of one-time revenue at Altera in the second quarter of 2025 caused most of the slowdown. The second test is whether Miller keeps finding acquisitions at the same hurdle rates while competition for targets stays strong. Spending on acquisitions was $1.91 billion in the first nine months of 2026, up from $755 million a year earlier. The full-year 2026 results, estimated for about February 6, 2027, give the next organic-growth reading. But proving the capital-allocation approach works without Leonard takes several years of results. So this discount likely takes several years to close fully.
- Risks
- Founder Mark Leonard resigned as President for health reasons in September 2025 and left the board in May 2026. Constellation's decentralized model depended heavily on his capital-allocation judgment. It is not yet proven under the new President, Mark Miller, over a full cycle.
Organic growth fell to 3% in Q2 2026 and 2% in Q3 2026. Management named a one-time item at Altera in Q2 2025, weak results at Dark Matter and Lumine, and customer losses in the US healthcare businesses, which it expects to continue. If growth does not recover, the compounding math behind the stock weakens.
Competition for acquisition targets stays strong. On the Q2 2026 call, management said that prices are a little weaker only for the largest targets. If Constellation cannot keep buying enough companies at attractive prices, it must deploy more cash into lower-return uses, which slows long-term compounding.
- Balance sheet
- Cash: $2.7B
Debt: $4.0B
Net debt: $1.3B
Net debt / EBITDA: 1.1× (low)
Undrawn credit line: $1.1B
Ratings: S&P BBB (positive outlook), Fitch BBB+ (stable outlook)
Constellation reports in US dollars and splits its debt into two groups. The parent must repay the first group. The second group sits inside subsidiaries without recourse to the parent. At September 30, 2026, total debt was $4.0 billion, down from $4.13 billion at December 31, 2025, and cash was $2.69 billion. Debt with recourse to the parent was $1.47 billion: $1.0 billion of unsecured senior notes due 2029 and 2034, $349 million (principal) of subordinated floating-rate debentures and an $86 million term loan. The other $2.53 billion had no recourse. It includes $136 million drawn on the Topicus revolving credit facility, $1.91 billion of bank loans of other operating groups, secured on their assets, and a $500 million 7% promissory note to Intercontinental Exchange from the Optimal Blue purchase, which matures in 2063. Subsidiaries with non-recourse debt held about $1.03 billion of the cash. The leverage ratio is S&P's figure for the 12 months to June 2026. The credit facility is the parent's $1,085 million unsecured facility, with nothing drawn and $13 million of letters of credit. The IRGA liability of $1.3 billion is also like debt. It is the value of the 29.38% of Topicus Coop that the Joday Group can put back to Constellation. This value moves with Topicus's results and share prices. On August 28, 2026, S&P changed the outlook to positive because leverage fell. Free cash flow available to shareholders was $1,522 million in the first nine months of 2026, and acquisitions used $1,913 million of cash. Acquisitions stay the main use of cash, and the low leverage leaves room to buy larger companies with debt.
As of Sep 30, 2026.
- Checkpoints
- Nov 6, 2026: Q3 2026 results: organic growth and acquisition spending. Failed. Watch: Organic growth of maintenance and recurring revenue back near 5% after currency effects (2% in Q2), as Mark Miller expects, passes; growth at or below 2% after currency effects or a lower pace of acquisitions fails. Outcome: Organic growth of maintenance and recurring revenue rose only to 4% after currency effects, below the rate near 5% that the test asked for, although acquisition spending rose.
Feb 6, 2027 (estimate): Full-year 2026 results and first annual letter under Miller. Pending. Watch: Organic growth in the second half of 2026 above the 3% of Q2 and a clear capital-allocation plan from Mark Miller pass; organic growth at or below 3% or weaker returns on acquisitions fail.
- Recent events
- Nov 6, 2026: Constellation reported Q3 2026 revenue of $3,512 million, up 19% from last year. Organic growth was 2%, and organic growth of maintenance and recurring revenue was 4% after currency effects, up from 2% in Q2. Altera and two US healthcare businesses bought in the quarter lost customers. Free cash flow available to shareholders was $443 million, down 16%. Constellation spent $484 million on acquisitions in the quarter and declared a dividend of $1.00 per share.
Oct 21, 2026: Constellation appointed Daan Dijkhuizen as Chief AI Officer and a member of its leadership team. He keeps his roles as CEO of the Topicus Operating Group and Managing Partner of VMS Ventures, Constellation's venture arm. His main task is to use VMS Ventures to invest in AI-native vertical market software businesses and to help the business units use AI in their products and operations.
Oct 16, 2026: Constellation said that it will release Q3 2026 results after the Toronto Stock Exchange closes on November 6, 2026. It will hold a conference call on November 9, 2026, at 8:00 a.m. ET.
Aug 28, 2026: S&P affirmed its BBB rating on Constellation Software and changed the outlook to positive from stable. S&P said net leverage fell to 1.1 times EBITDA for the 12 months to June 2026.
Aug 12, 2026: Constellation held a quarterly conference call. Mark Miller said the company will not give an AI target, an AI revenue line or an AI timeline. He said AI has not yet given a real increase in organic growth, and that hurdle rates for acquisitions do not change.
Aug 11, 2026: Constellation reported Q2 2026 revenue of $3,335 million, up 17% from last year. Organic growth was 3%, or 1% after currency effects. Management said most of the slowdown came from Altera, which had $17 million of one-time revenue in Q2 2025. Free cash flow available to shareholders was $345 million.
May 15, 2026: Mark Leonard left the board at the annual meeting. He did not stand for re-election, as the company said on March 27, 2026. He stays as an advisor for the company's long-term minority stakes in other companies.
Sep 25, 2025: Mark Leonard resigned as President for health reasons and stayed on the board. The board appointed Mark Miller as President. Miller is the Chief Operating Officer and kept that role. He has been on the leadership team for over 30 years.